The anandamide membrane transporter and the therapeutic implications of its inhibition

Therapy

Volumn 2, Issue 1, 2005, Pages 141-150

  Battista, Natalia ^a   Gasperi, Valeria ^b   Fezza, Filomena ^b   Maccarrone, Mauro ^a  

^a UNIVERSITY OF TERAMO   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

AM1172; AM404; Anandamide; Arvanil; Cannabinoid receptors; Fatty acid amide hydrolase; Membrane transport; Neurodegenerative disease; O 2109; Olvanil; OMDM1; OMDM2; Therapy; UCM707; Vanilloid receptor; VDM11; VDM13

Indexed keywords

AM 1172; ANANDAMIDE; ANANDAMIDE MEMBRANE TRANSPORTER; ANANDAMIDE MEMBRANE TRANSPORTER INHIBITOR; ARVANIL; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AFFECTING AGENT; CARRIER PROTEIN; DRONABINOL; FATTY ACID AMIDASE; LEVODOPA; N (3 FURYLMETHYL)ARACHIDONAMIDE; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; N 5,8,11,14 EICOSATETRAENYL 4 HYDROXYBENZAMIDE; N OLEOYLETHANOLAMINE; O 2109; OLVANIL; OMDM 1; OMDM 2; OMDM 3; OMDM 4; PHLORETIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VANILLOID RECEPTOR; VDM 13;

ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; CONCENTRATION RESPONSE; DEGENERATIVE DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSPORT; GLAUCOMA; HUMAN; HUNTINGTON CHOREA; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 13444252856     PISSN: 14750708     EISSN: None     Source Type: Journal    
DOI: 10.1586/14750708.2.1.141     Document Type: Review

References (74)

1. Devane W, Hanus I, Breuer A et al. Isolation and structure of a brain constituent that binds to cannabinoid receptor. Science 258 (5090), 1946-1949 (1992).
2. Mechoulam R, Gaoni Y. A total synthesis of dl E-1tetrahydrocannabinol, the active constituent of hashish. J. Am. Chem. Soc. 87, 3273-3275 (1965).
3. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346(6284), 561-564 (1990).
4. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a pheripheral receptor for cannabinoids. Nature 365(6441), 61-65 (1993).
5. Maccarrone M, Lorenzon T, Bari M, Melino G, Finazzi-Agrö A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J. Biol. Chem. 275(41), 31938-31945 (2000).
6. Di Marzo V, Fontana A, Cadas H et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372(6507), 686-691 (1994).
7. Melck D, Bisogno T, De Petrocellis L et al. Unsaturated long-cham N-acyl-vanillylamides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-transport and bind to CB1 cannabinoid receptors. Biochem. Biophys. Res. Comm. 262(1), 275-284 (1999).
8. Van der Stelt M, Di Marzo V. Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur. J. Biochem. 271(10), 1827-1834 (2004).
9. 31P NMR and enzyme activity study. J. Lipid. Res. 41(6), 985-990 (2000).
10. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Molecular characterization of a phospholipase D generating anandamide and Its congeners. J. Biol. Chem. 279(7), 5298-5305 (2004).
11. Hillard CJ, Edgemond WS, Jarrahian A, Campbell WB. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J. Neurochem. 69(2), 631-638 (1997).
12. Beltramo M, Stella N, Calignano A Lin SY, Makriyannis A, Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277(5329), 1094-1097 (1997).
13. Deutsch DG, Chin SA. Enzymatic syntesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46(5), 791-796 (1993).
14. Desarnaud F, Cadas H, Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. J. Biol. Chem. 270(11), 6030-6035 (1995).
15. Ueda N, Kurahashi Y, Yamamoto S, Tokunaga TJ. Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. J Biol. Chem. 270(40), 23823-23827 (1995).
16. Ueda N, Puffenbarger RA, Yamamoto S, Deutsch DG. The fatty acid amide hydrolase (FAAH). Chem. Phys. Lipids 108(1-2), 107-121 (2000).
17. Bracey MH, Hanson MA, Masuda KR, Stevens RC, Cravatt BF. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 298(5599), 1793-1796 (2002).
18. Giang DK, Cravatt BF. Molecular characterization of human and mouse fatty acid amide hydrolases. Proc. Natl Acad. Sci. USA 94(6 , 2238-2242 (1994).
19. Hillard CJ, Wilkinson DM, Edgemond WS, Campbell WB. Characterization of the kinetics and distribution of N- arachidonylethanolamine (anandamide) hydrolysis by rat brain. Biochim. Biophys. Acta 1257(3), 249-256 (1995).
20. Waleh NS, Cravatt BF, Apte-Deshpande A, Terao A, Kilduff TS. Transcriptional regulation of the mouse fatty acid amide hydrolase gene. Gene 291(1-2), 203-210 (2002).
21. Maccarrone M, Bari M, Di Rienzo M, Finazzi-Agrò A, Rossi A. Progesterone activates fatty acid amide hydrolase (FAAH) promoter in human T-lymphocytes through the transcription factor ikaros. J. Biol. Chem. 278(35), 32726-32732 (2003).
22. Piomelli D, Beltramo M, Glasnapp S et al. Structural determinants for recognition and traslocation by anandamide transporter. Proc. Natl Acad. Sci. USA 96(10), 4188-4192 (1999).
23. Maccarrone M, van der Stelt M, Rossi A, Veldink GA, Vliegenthart JF, Finazzi-Agrò A. Anandamide hydrolysis by human cells in culture and brain. J. Biol. Chem. 273(48), 32332-32339 (1998).
24. Beltramo M, De Fonseca FR, Navarro M et al. Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J. Neurosci. 20(9), 3401-3407 (2000).
25. Maccarrone M, Attina M, Bari M, Cartoni A, Ledent C, Finazzi-Agrò A. Anandamide degradation and N-acylethanolamines level in wild-type and CB (1) cannabinoid receptor knockout mice of different ages. J. Neurochem. 78(2), 339-348 (2001).
26. Battista N, Bari M, Finazzi-Agrò A, Maccarrone M. Anandamide uptake by synaptosomes from human, mouse and rat brain: inhibition by glutamine and glutamate. Lipids Health Dis. 1(1), 1-3 (2002).
27. Maccarrone M, Bari M, Battista N Finazzi Agrò A. Estrogen stimulates arachidonoylethanolamide release from human endothelial cells and platelet activation. Blood 100(12), 4040-4048 (2002).
28. Maccarrone M, Fiorucci L, Erba F, Bari M, Finazzi-Agrò A, Ascoli F. Human mast cells take up and hydrolyze anandamide under the control of 5-lipoxygenase and do not express cannabinoid receptors. FEBS Lett. 468(2-3), 176-180 (2000).
29. Rakhshan F, Day TA, Blakely RD, Barker EL. Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. J. Pharmacol. Exp. Ther. 292(3), 960-967 (2000).
30. Ruiz-Llorente L, Ortega-Gutierrez S, Viso A et al. Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: synthesis of new transporter inhibitors as tools for this study. Br. J. Pharmacol. 141(3), 457-467 (2004).
31. Beltramo M, Piomelli D. Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport 11(6), 1231-1235 (2000).
32. Hajos N, Kathuria S, Dinh T et al. Endocannabinoid transport tightly controls 2-arachidonoyl glycerol actions in the hippocampus: effects of low temperature and the transport inhibitor AM404. Eur. J. Neurosci. 19(11), 2991-2996 (2004).
33. Fasia L, Karava V, Siafaka-Kapadai A. Uptake and metabolism of [3H]anandamide by rabbit platelets. Lack of transporter? Eur. J. Biochem. 270(17), 3498-3506 (2003).
34. Maccarrone M, Bari M, Menichelli A, Del Principe D, Finazzi-Agrò A. Anandamide activates human platelets through a pathway independent of the arachidonate cascade. FEBS Lett. 447(2-3), 277-282 (1999).
35. Maccarrone M, Bari M, Menichelli A, Giuliani E, Del Principe D, Finazzi-Agrò A. Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor. Eur. J. Biochem. 268(3), 819-825 (2001).
36. Day T A, Rakhshan F, Deutsch DG, Barker EL. Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Mol. Pharmacol. 59(6), 1369-1375 (2001).
37. Deutsch DG, Glaser ST, Howell JM et al. The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. J. Biol. Chem. 276(10), 6967-6973 (2001).
38. Glaser S, Abumrad N, Fatade F, Kaczocha M, Studholme KM, Deutsch DG. Evidence against the presence of an anandamide transporter. Proc. Natl Acad. Sci. USA. 100(7), 4269-4274 (2003).
39. Patricelli MP, Cravatt BF. Proteins regulating the biosynthesis and inactivation of neuromodulatory fatty acid amides. Vit. Horm. 62, 95-131 (2001).
40. Fegley D, Kathuria S, Mercier CL et al. Anandamide transport is independent of fatty acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc. Natl Acad. Sci. USA 101(23), 8756-8761 (2004).
41. Ligresti A, Morera E, van der Stelt M et al. Further evidence for existence of a specific process for the membrane transport of anandamide. Biochem. J. 380(Pt 1), 265-272 (2004).
42. Ortega-Gutierrez S, Hawkins EG, Viso A, Lopez-Rodriguez ML, Cravatt BF. Comparison of anandamide transport in FAAH wild-type and knockout neurons for contributions by both FAAH and the CB1 receptor to anandamide uptake. Biochemistry 43(25), 8184-8190 (2004).
43. Gerdeman GL, Ronesi J, Lovinger DM. Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nature Neurosci. 5(5), 446-451 (2002).
44. Maccarrone M, Bari M, Lorenzon T, Bisogno T, Di Marzo V, Finazzi-Agrò A. Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J. Biol. Chem. 275(18), 13484-13492 (2000).
45. Giuffrida A, Rodriguez de Fonseca F, Nava F, Loubet-Lescoulie P, Piomelli D. Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. Eur. J. Pharmacol. 408(2) 161-168 (2000).
46. Smart D, Jerman JC. Anandamide an endogenous activator of the vanilloid receptor. Trends Pharmacol. Sci. 21(4), 34 (2000).
47. Zygmunt PM, Chuang H, Movahed P, Julius D, Hogestatt ED. The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur. J. Pharmacol. 396(1), 39-42 (2000).
48. Di Marzo V, Griffin G, De Petrocellis L et al. A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. J. Pharmacol. Exp. Ther. 300(3), 984-991 (2002).
49. Di Marzo V, Bisogno T, Melck D et al. Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett. 436(3), 449-454 (1998).
50. De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Di Marzo V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS 483(1), 52-56 (2000).
51. Lopez-Rodriguez ML, Viso A, Ortega G et al. Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. J. Med. Chem. 44(26), 4505-4508 (2001).
52. de Lago E, Fernandez-Ruiz J, Ortega-Gutierrez S, Viso A, Lopez-Rodriguez ML, Ramos JA. UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. Eur. J. Pharmacol. 449(1-2), 99-103 (2002).
53. Ortar G, Ligresti A, De Petrocellis L, Morera E, Di Marzo V. Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem. Pharmacol. 65(9), 1473-1481 (2003).
54. Gaetani S, Cuomo V, Piomelli D. Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends Mol. Med. 11, 9474-9478 (2003).
55. De Petrocellis L, Bisogno T, Maccarrone M, Davis JB, Finazzi-Agro A, Di Marzo V. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J. Biol Chem. 276(16), 12856-12863 (2001).
56. Ahluwalia J, Yaqoob M, Urban L et al. Activation of capsaicin-sensitive primary sensory neurones induces anandamide production and release. J. Neurochem. 84(3), 585-591 (2003).
57. Lastres-Becker I, de Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V, Fernandez-Ruiz J. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. J. Neurochem. 84(5), 1097-109 (2003).
58. Gonzalez S, Romero J, de Miguel R et al. Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide. Life Sci. 65(3), 327-336 (1999).
59. Lastres-Becker I, Berrendero F, Lucas JJ et al. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease. Brain Res. 929(2), 236-242 (2002).
60. De Lago E, Cebeira M, Ortega S et al. International Cannabinoid Research Symposium. Paestum, SA, Italy (2004).
61. Baker D, Pryce G, Croxford JL et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15(2), 300-302 (2001).
62. Gubellini P, Picconi B, Bari M et al. Experimental Parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J. Neurosci. 22(16), 6900-6907 (2002).
63. Maccarrone M, Gubellini P, Bari M et al. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J. Neurochem. 85(4), 1018-1025 (2003).
64. Fernandez-Espejo E, Caraballo I, Rodriguez de Fonseca F et al. Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function. Neuropsychopharmacolog. 29(6), 1134-1142 (2004).
65. Battista N, Fezza F, Maccarrone M. Endocannabinoids and their Involvement in the Neurovascular System. Curr. Neurovascular Res. 1, 129-140 (2004).
66. Laine K, Jarvinen T, Savinainen J, Laitinen JT, Pate DW, Jarvinen K. Effects of topical anandamide-transport inhibitors, AM404 and olvanil, on intraocular pressure 'in normotensive rabbits. Pharm. Res. 18 (4), 494-499 (2001).
67. Van der Stelt M, Veldhuis WB, Maccarrone M et al. Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol. 26(2-3), 317-346 (2002).
68. Mechoulam R, Spatz M, Shohami E. Endocannabinoids and neuroprotection. Sci STKE. 23(129), RE5 (2002).
69. Croxford JL. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 17(3), 179-202 (2003).
70. Veldhuis WB, van der Stelt M, Wadman MW et al. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases. J. Neurosci. 23(10), 4127-4133 (2003).
71. Howlett AC, Barth F, Bonner TI et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 54(2), 161-202 (2002).
72. Marsicano G, Goodenough S, Monory K et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science. 302(5642), 84-88 (2003).
73. Izzo AA, Capasso F, Costagliola A et al. An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology 125(3), 765-774 (2003).
74. Bifulco M, Laezza C, Valenti M, Ligresti A, Portella G, Di Marzo V. A new strategy to block tumor growth by inhibiting cndocannabinoid inactivation. FASEB J. 18(13), 1606-1608 (2004).